Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Advisory committee schedule

This article was originally published in The Tan Sheet

Executive Summary

FDA's Nonprescription Drugs Advisory Committee is slated for meetings in March and June, with specific dates to be announced, according to a tentative schedule of advisory committee meetings published in the Dec. 31 Federal Register. Possible overlaps with other committees may include the Endocrinologic & Metabolic Drugs Advisory Committee, slated to meet June 22-23, the Dermatologic & Ophthalmic Drugs Advisory Committee (June 24-25) and the Pulmonary-Allergy Drugs Advisory Committee, scheduled for June 29-30...

You may also be interested in...



NDAC schedule

Previously announced tentative meeting date in March has been cancelled, according to FDA. Still on the calendar is a meeting in June with the day yet to be announced. Preliminary meeting dates for 2004 appeared in Federal Register late last year (1"The Tan Sheet" Jan. 12, 2004, In Brief)...

Statins Improve Survival Rate In Trial, Could Strengthen OTC Platform

Statin therapy in patients with systolic heart failure may improve survival without the need for "urgent" heart transplants, according to a study published in the Journal of the American College of Cardiology Feb. 18

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel